Neuroscience News and Research

RSS

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

New hope for chronic pain sufferers

In an Anglo-Italian study, thirty healthy subjects were invited to look at either their own hand, the experimenter's hand, or an object, while their hand was subjected to laser-induced pain.

30 Oct 2009

Researchers discover new bend in gene control

Since the completion of the human genome sequence, a question has baffled researchers studying gene control: How is it that humans, being far more complex than the lowly yeast, do not proportionally contain in our genome significantly more gene-control proteins?

30 Oct 2009

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.

30 Oct 2009

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

The House Judiciary Committee today called upon national experts and stakeholders in the fields of science and sport to better understand the effects of head injuries on players in the National Football League (NFL). Nationally recognized sports physician and neurosurgeon, Julian E. Bailes, M.D. was called to provide expert testimony based on decades of research detailing how repetitive head trauma on the field leads to long-term neurological damage among athletes.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

FDA issues a Complete Response Letter regarding NDA for Intermezzo

Transcept Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet).

29 Oct 2009

Brain cell transplants help replace degenerated neurons, finds Swiss research team

A Swiss research team has found that using an animal's own brain cells (autologous transplant) to replace degenerated neurons in select brain areas of donor primates with simulated but asymptomatic Parkinson's disease and previously in a motor cortex lesion model, provides a degree of brain protection and may be useful in repairing brain lesions and restoring function.

29 Oct 2009

CAMH Foundation receives $5 million gift for mental health research

An extraordinary gift of $5 million from Mr. G. Raymond Chang, Chancellor of Ryerson University and Chair of CI Financial, will go toward furthering research and education about the treatment of mental health and addictions, the Centre for Addiction and Mental Health (CAMH) Foundation announced today.

29 Oct 2009

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Rutgers scientist receives 2009 Gruber International Research Award

For the first time, it now is possible for researchers to peer into those internal processes in a rodent brain. Eva Pastalkova, a post-doctoral researcher at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark and her advisor, Professor Gy-rgy Buzsaki, have developed a method for studying internally generated brain activity in rats.

28 Oct 2009

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

Culture-based treatment may be effective for reducing depression

A genetic tendency to depression is much less likely to be realized in a culture centered on collectivistic rather than individualistic values, according to a new Northwestern University study.

28 Oct 2009

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

King Pharmaceuticals, Inc. announced today that it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.

28 Oct 2009

GE’s AgileTrac Asset Manager and Enterprise Capacity Management Solution adopted by Virtua Healthcare

Virtua and GE Healthcare announced today that they are collaborating to implement new solutions to help increase efficiencies, lower healthcare costs and improve patient care throughout the health system. Virtua is adopting GE’s AgileTracTM Asset Manager and Enterprise Capacity Management Solution, an automated workflow solution that allows healthcare staff to better track a patient’s inpatient experience, as well as manage the hospital’s assets, ultimately reducing costs and increasing patient satisfaction.

27 Oct 2009

CWRU grants licensing agreement to Bioptigen for FDOCT technology

Case Western Reserve University and University Hospitals Case Medical Center have granted to Bioptigen, of Research Triangle Park, N.C ., an exclusive intellectual property licensing agreement for Fourier domain optical coherence tomography (FDOCT), an imaging technology developed from research at the university's Department of Biomedical Engineering.

27 Oct 2009

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.

27 Oct 2009

Genetic mutations cause for SIDS and SUDS

Scientists and clinicians at the Montefiore-Einstein Center for Cardiogenetics have teamed up and found that genetic mutations leading to Long QT Syndrome (LQTS) could be causing electrical malfunctioning of the heart resulting in the mysterious deaths more commonly known as Sudden Infant Death Syndrome (SIDS) and Sudden Unexplained Death Syndrome (SUDS) in people older than 12 months of age.

27 Oct 2009

Neuroscience News and Research

Eisai reports global Phase III study results of eribulin mesylate

New hope for chronic pain sufferers

Researchers discover new bend in gene control

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

FDA issues a Complete Response Letter regarding NDA for Intermezzo

Brain cell transplants help replace degenerated neurons, finds Swiss research team

CAMH Foundation receives $5 million gift for mental health research

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Rutgers scientist receives 2009 Gruber International Research Award

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

Data from Phase II clinical trial of NKTR-118 presented

Culture-based treatment may be effective for reducing depression

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

GE’s AgileTrac Asset Manager and Enterprise Capacity Management Solution adopted by Virtua Healthcare

CWRU grants licensing agreement to Bioptigen for FDOCT technology

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

Genetic mutations cause for SIDS and SUDS

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News